Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 – 2010)

Bibliography

• Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004;10:S122-9
   PubMed Web of Science ®Google Scholar
• Voss A, Doebbeling BN. The worldwide prevalence of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1995;5:101-6
   PubMed Web of Science ®Google Scholar
• Yoshida R, Kaku M, Kohno S, Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrob Agents Chemother 1995;39:1196-8
   PubMedGoogle Scholar
• Johnson R, Streicher EM, Louw GE, Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006;8:97-111
   PubMed Web of Science ®Google Scholar
• Dessen A, Quemard A, Blanchard JS, Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995;267:1638-41
   PubMed Web of Science ®Google Scholar
• Heath RJ, Rock CO, Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs 2004;5:146-53
   PubMedGoogle Scholar
• Wright HT, Reynolds KA, Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol 2007;10:447-53
   PubMed Web of Science ®Google Scholar
• Smith S, Witkowski A, Joshi AK, Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res 2003;42:289-317
   PubMed Web of Science ®Google Scholar
• White SW, Zheng J, Zhang YM, The structural biology of type II fatty acid biosynthesis. Annu Rev Biochem 2005;74:791-831
   PubMed Web of Science ®Google Scholar
• Campbell JW, Cronan JE Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu Rev Microbiol 2001;55:305-32
   PubMed Web of Science ®Google Scholar
• Magnuson K, Jackowski S, Rock CO, Regulation of fatty acid biosynthesis in Escherichia coli. Microbiol Rev 1993;57:522-42
   PubMedGoogle Scholar
• Heath RJ, White SW, Rock CO. Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 2001;40:467-97
   PubMed Web of Science ®Google Scholar
• Heath RJ, Rock CO. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J Biol Chem 1995;270:26538-42
   PubMed Web of Science ®Google Scholar
• Heath RJ, Li J, Roland GE, Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J Biol Chem 2000;275:4654-9
   PubMed Web of Science ®Google Scholar
• Dessen A, Quemard A, Blanchard JS, Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995;267:1638-41
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Laing NM, Baudry T, In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 2007;51:1580-1
   PubMed Web of Science ®Google Scholar
• Park HS, Yoon YM, Jung SJ, CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. Int J Antimicrob Agents 2007;30:446-51
   Google Scholar
• Roujeinikova A, Levy CW, Rowsell S, Crystallographic analysis of triclosan bound to enoyl reductase. J Mol Biol 1999;294:527-35
   PubMed Web of Science ®Google Scholar
• Albert Einstein College of Medicine of Yeshive University. Crystallize InhA enzyme-NADH complex. US5556778; 1996
   Google Scholar
• Priyadarshi A, Kim EE, Hwang KY. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan. Proteins 2010;78:480-6
   Google Scholar
• Kumar G, Parasuraman P, Sharma SK, Discovery of a rhodamine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. J Med Chem 2007;50:2665-75
   PubMed Web of Science ®Google Scholar
• Tipparaju SK, Mulhearn DC, Klein GM, Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase. ChemMedChem 2008;3:1250-68
   Google Scholar
• Lu H, England K, am Ende C, Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. ACS Chem Biol 2009;4:221-31
   PubMed Web of Science ®Google Scholar
• Tipparaju SK, Muench SP, Mui EJ, Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem 2010;53:6287-300
   PubMed Web of Science ®Google Scholar
• Marrakchi H, Dewolf WE Jr, Quinn C, Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem J 2003;370:1055-62
   PubMed Web of Science ®Google Scholar
• Kim KH, Park JK, Ha BH, Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007;63:246-8
   Google Scholar
• Massengo-Tiasse RP, Cronan JE. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase. J Biol Chem 2008;283:1308-16
   Google Scholar
• Lu H, Tonge PJ. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei. Biochemistry 2010;49:1281-9
   PubMed Web of Science ®Google Scholar
• Priyadarshi A, Kim EE, Hwang KY. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan. Proteins 2003;78:480-6
   Google Scholar
• Parikh S, Moynihan DP, Xiao G, Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 1999;38:13623-34
   PubMed Web of Science ®Google Scholar
• Qiu X, Janson CA, Court RI, Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci 1999;8:2529-32
   PubMed Web of Science ®Google Scholar
• Rozwarski DA, Vilcheze C, Sugantino M, Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J Biol Chem 1999;274:15582-9
   PubMed Web of Science ®Google Scholar
• Kuo MR, Morbidoni HR, Alland D, Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 2003;278:20851-9
   PubMed Web of Science ®Google Scholar
• Lu XY, You QD, Chen YD. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis. Mini Rev Med Chem 2010;10:181-92
   Google Scholar
• Research Foundation of State Univeristy of New York. Diphenyl ether antimicrobial compounds. US20060041025; 2006
   Google Scholar
• Sullivan TJ, Truglio JJ, Boyne ME, High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 2006;1:43-53
   PubMed Web of Science ®Google Scholar
• am Ende CW, Knudson SE, Liu N, Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett 2008;18:3029-33
   PubMed Web of Science ®Google Scholar
• Freundlich JS, Wang F, Vilcheze C, Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem 2009;4:241-8
   PubMed Web of Science ®Google Scholar
• Kini SG, Bhat AR, Bryant B, Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives. Eur J Med Chem 2009;44:492-500
   PubMed Web of Science ®Google Scholar
• Mutabilis SA. New hydroxyphenyl derivatives and biological applications thereof. WO2007135562; 2007
   Google Scholar
• Rafi SB, Cui G, Song K, Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase. J Med Chem 2006;49:4574-80
   PubMed Web of Science ®Google Scholar
• Chhibber M, Kumar G, Parasuraman P, Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg Med Chem 2006;14:8086-98
   PubMed Web of Science ®Google Scholar
• Miller WH, Seefeld MA, Newlander KA, Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem 2002;45:3246-56
   PubMed Web of Science ®Google Scholar
• Seefeld MA, Miller WH, Newlander KA, Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem 2003;46:1627-35
   PubMed Web of Science ®Google Scholar
• Smithkline Deecham Corp. FabI inhibitors. WO2001026652; 2001
   Google Scholar
• Payne DJ, Miller WH, Berry V, Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother 2002;46:3118-24
   PubMed Web of Science ®Google Scholar
• Affinium Pharm, Inc. Heterocyclic compounds, methods of making them and their use in therapy. WO2004052890; 2004
   Google Scholar
• Sampson PB, Picard C, Handerson S, Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI). Bioorg Med Chem Lett 2009;19:5355-8
   Google Scholar
• Affinium Pharm, Inc. Therapeutic agents, and methods of making and using the same. WO2007067416; 2007
   Google Scholar
• Ramnauth J, Surman MD, Sampson PB, 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI. Bioorg Med Chem Lett 2009;19:5359-62
   Google Scholar
• Affinium Pharm, Inc. Therapeutic agents, and methods of making and suing the same. WO2007053131; 2007
   Google Scholar
• Affinium Pharm, Inc. Compositions comprising multiple biology agents, and methods of using the same. US20060142265; 2006
   Google Scholar
• Affinium Pharm, Inc. Acrylamide derivatives as FabI inhibitors. WO2008009122; 2008
   Google Scholar
• He X, Alian A, Stroud R, Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J Med Chem 2006;49:6308-23
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Kumura K, Takahata S, 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. Bioorg Med Chem 2007;15:1106-16
   Google Scholar
• Meiji Seika Kaisha. Novel inhibitor of FabK and FabI/K. WO2007086584; 2007
   Google Scholar
• Kitagawa H, Ozawa T, Takahata S, Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK. J Med Chem 2007;50:4710-20
   PubMed Web of Science ®Google Scholar
• Rozwarski DA, Grant GA, Barton DH, Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998;279:98-102
   PubMed Web of Science ®Google Scholar
• Lei B, Wei CJ, Tu SC. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J Biol Chem 2000;275:2520-6
   PubMed Web of Science ®Google Scholar
• Nguyen M, Claparols C, Bernadou J, A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts. Chembiochem 2001;2:877-83
   Google Scholar
• Bonnac L, Gao GY, Chen L, Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis. Bioorg Med Chem Lett 2007;17:4588-91
   Google Scholar
• Broussy S, Bernardes-Genisson V, Quemard A, The first chemical synthesis of the core structure of the benzoylhydrazine-NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase. J Org Chem 2005;70:10502-10
   Google Scholar
• Delaine T, Bernardes-Genisson V, Quemard A, Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents. Eur J Med Chem 2010;45:4554-61
   PubMed Web of Science ®Google Scholar
• Centre Nat Rech Scient. Novel anti-infectious derivatives, method for the production thereof, pharmaceutical compositions containing same and uses of said derivatives in treatment. WO2009101345; 2009
   Google Scholar
• Nat Inst Immunology. 2-Thioxothiazolidin-4-onecompounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP deductase of type II fatty acid synthesis pathway and other cell growth pathways. US20080051445; 2008
   Google Scholar
• Nat Inst Immunology. 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways. EP1834642; 2007
   Google Scholar
• Genome Therapeutics Corp. Antibacterial FabI inhibitors. WO2004064837; 2004
   Google Scholar
• Ling LL, Xian J, Ali S, Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother 2004;48:1541-7
   PubMed Web of Science ®Google Scholar
• Lu XY, Chen YD, Jiang YJ, Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem 2009;44:3718-30
   Google Scholar
• Lu XY, Chen YD, You QD. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment. Chem Biol Drug Des 2010;75:195-203
   Google Scholar